Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
